Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First European trial for new breast cancer vaccine

20.03.2002


European clinical trials are under way in Denmark and the UK testing a new breast cancer vaccine targeted against the HER-2 growth factor.



HER-2 is overexpressed in about a quarter of all breast cancers and has become a key target for new treatments, such as the monoclonal antibody therapy Herceptin.

But, the development of a vaccine by Danish pharmaceutical company Pharmexa represents an entirely novel treatment paradigm, according to Pharmexa’s manager of preclinical development and immunopharmacology, Dr Dana Leach.


He told a news briefing at the 3rd European Breast Cancer Conference in Barcelona: "The objective of our vaccine is to stimulate the patient’s own immune system and to see whether we can induce it to launch specific killer cells as well as producing HER-2 specific antibodies. This is a phase I/II trial. Our first objective is to test the safety of the vaccine, but we also want to make a preliminary evaluation of the vaccine’s ability to raise an immune response. There are 27 patients with advanced breast cancer in the trial, which should be completed late this year."

HER-2 is a protein that is overexpressed in many tumours. But, because it is also expressed at low levels in some normal tissues, the immune system does not recognise it as foreign and the immune cells, especially helper T cells that initiate the immune response, are simply not around to launch an attack. So, the vaccine – AutoVac – has been designed to help kick-start the immune response by giving the T cells a foreign agent to recognise and react against. The aim is that the immune system then recognises the overexpressed HER-2 in the cancer cells and attacks them, but ignores the normal tissue because that contains only low levels.

Dr Leach said that animal tests had shown that the vaccine produced a specific immune response and there had been no adverse side effects.

The vaccine consists of two small inactive fragments derived from tetanus toxin – the bacterium that causes lockjaw. The researchers included DNA encoding the fragments, into DNA that they had made in the laboratory to code for a portion of the HER-2 molecule. The DNA vaccine is injected and taken up by the cells, which then manufacture the protein, including the inserted tetanus fragments that ‘wake up’ the immune system and help it to respond to HER-2.

Dr Leach said the company was also preparing to start clinical trials in a variation of this approach. Instead of a DNA vaccine that prompts the body’s cells to make the necessary protein, the AutoVac protein will be made beforehand in the laboratory and injected directly as a vaccine into the patient.

"Each approach has potential advantages – DNA is generally believed to be a good way to get a response from cytotoxic T cells, while protein is better at inducing antibody responses," he said. "We have to look at tackling cancer from as many different approaches as possible because different tumours react in different ways. We know that already from the variable responses to chemotherapy, radiotherapy, endocrine treatment and other immunotherapies. But, as we get better at diagnosis and understanding the genetic make-up of tumours it should become possible to make better predictions about which treatment is best for which patient and to combine treatments that work synergistically to boost effectiveness."

Dr Leach said that the success of the drug Herceptin as a treatment had shown that HER-2 was a good target. "Although it is early days yet, any time that you can successfully take a new cancer vaccine into the clinic it is an important and exciting event."

Margaret Willson | alphagalileo

More articles from Health and Medicine:

nachricht Deep stimulation improves cognitive control by augmenting brain rhythms
04.04.2019 | Picower Institute at MIT

nachricht Black nanoparticles slow the growth of tumors
04.04.2019 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explosion on Jupiter-sized star 10 times more powerful than ever seen on our sun

A stellar flare 10 times more powerful than anything seen on our sun has burst from an ultracool star almost the same size as Jupiter

  • Coolest and smallest star to produce a superflare found
  • Star is a tenth of the radius of our Sun
  • Researchers led by University of Warwick could only see...

Im Focus: Quantum simulation more stable than expected

A localization phenomenon boosts the accuracy of solving quantum many-body problems with quantum computers which are otherwise challenging for conventional computers. This brings such digital quantum simulation within reach on quantum devices available today.

Quantum computers promise to solve certain computational problems exponentially faster than any classical machine. “A particularly promising application is the...

Im Focus: Largest, fastest array of microscopic 'traffic cops' for optical communications

The technology could revolutionize how information travels through data centers and artificial intelligence networks

Engineers at the University of California, Berkeley have built a new photonic switch that can control the direction of light passing through optical fibers...

Im Focus: A long-distance relationship in femtoseconds

Physicists observe how electron-hole pairs drift apart at ultrafast speed, but still remain strongly bound.

Modern electronics relies on ultrafast charge motion on ever shorter length scales. Physicists from Regensburg and Gothenburg have now succeeded in resolving a...

Im Focus: Researchers 3D print metamaterials with novel optical properties

Engineers create novel optical devices, including a moth eye-inspired omnidirectional microwave antenna

A team of engineers at Tufts University has developed a series of 3D printed metamaterials with unique microwave or optical properties that go beyond what is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

Fraunhofer FHR at the IEEE Radar Conference 2019 in Boston, USA

09.04.2019 | Event News

 
Latest News

New automated biological-sample analysis systems to accelerate disease detection

18.04.2019 | Life Sciences

Explosion on Jupiter-sized star 10 times more powerful than ever seen on our sun

18.04.2019 | Physics and Astronomy

New eDNA technology used to quickly assess coral reefs

18.04.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>